ADAM17 and coronary atherosclerosis: A major obstacle to a human sample study is due to the co-existence of extensive coronary atherosclerosis and DCM in almost all patients with advanced diabetes and it is difficult, if not impossible, to differentiate the effect of ADAM17 on ischemic and diabetic cardiomyopathy.